These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 31328345)

  • 21. Varenicline treatment for methamphetamine dependence: A randomized, double-blind phase II clinical trial.
    Briones M; Shoptaw S; Cook R; Worley M; Swanson AN; Moody DE; Fang WB; Tsuang J; Furst B; Heinzerling K
    Drug Alcohol Depend; 2018 Aug; 189():30-36. PubMed ID: 29860057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacotherapy of amphetamine-type stimulant dependence: an update.
    Brensilver M; Heinzerling KG; Shoptaw S
    Drug Alcohol Rev; 2013 Sep; 32(5):449-60. PubMed ID: 23617468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study.
    Ray LA; Bujarski S; Courtney KE; Moallem NR; Lunny K; Roche D; Leventhal AM; Shoptaw S; Heinzerling K; London ED; Miotto K
    Neuropsychopharmacology; 2015 Sep; 40(10):2347-56. PubMed ID: 25801501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation.
    Adi Y; Juarez-Garcia A; Wang D; Jowett S; Frew E; Day E; Bayliss S; Roberts T; Burls A
    Health Technol Assess; 2007 Feb; 11(6):iii-iv, 1-85. PubMed ID: 17280624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Second-generation antidepressants for preventing seasonal affective disorder in adults.
    Gartlehner G; Nussbaumer B; Gaynes BN; Forneris CA; Morgan LC; Kaminski-Hartenthaler A; Greenblatt A; Wipplinger J; Lux LJ; Sonis JH; Hofmann J; Van Noord MG; Winkler D
    Cochrane Database Syst Rev; 2015 Nov; (11):CD011268. PubMed ID: 26558418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation.
    Stead LF; Koilpillai P; Lancaster T
    Cochrane Database Syst Rev; 2015 Oct; (10):CD009670. PubMed ID: 26457723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paradoxes of evidence in Russian addiction medicine.
    Mendelevich VD; Zalmunin KY
    Int J Risk Saf Med; 2015; 27 Suppl 1():S102-3. PubMed ID: 26639682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized, Placebo-Controlled Trial of Targeting Neuroinflammation with Ibudilast to Treat Methamphetamine Use Disorder.
    Heinzerling KG; Briones M; Thames AD; Hinkin CH; Zhu T; Wu YN; Shoptaw SJ
    J Neuroimmune Pharmacol; 2020 Jun; 15(2):238-248. PubMed ID: 31820289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychosocial interventions for cannabis use disorder.
    Gates PJ; Sabioni P; Copeland J; Le Foll B; Gowing L
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD005336. PubMed ID: 27149547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interventions for preventing weight gain after smoking cessation.
    Parsons AC; Shraim M; Inglis J; Aveyard P; Hajek P
    Cochrane Database Syst Rev; 2009 Jan; (1):CD006219. PubMed ID: 19160269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anticonvulsants or Antidepressants in Combination Pharmacotherapy for Treatment of Neuropathic Pain in Cancer Patients: A Systematic Review and Meta-analysis.
    Guan J; Tanaka S; Kawakami K
    Clin J Pain; 2016 Aug; 32(8):719-25. PubMed ID: 26491936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extended-release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo-controlled trial.
    Coffin PO; Santos GM; Hern J; Vittinghoff E; Santos D; Matheson T; Colfax G; Batki SL
    Addiction; 2018 Feb; 113(2):268-278. PubMed ID: 28734107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patterns of reduced use and abstinence in multi-site randomized controlled trials of pharmacotherapies for cocaine and methamphetamine use disorders.
    Amin-Esmaeili M; Susukida R; Johnson RM; Farokhnia M; Crum RM; Thrul J; Mojtabai R
    Drug Alcohol Depend; 2021 Sep; 226():108904. PubMed ID: 34304121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of stimulant use disorder: A systematic review of reviews.
    Ronsley C; Nolan S; Knight R; Hayashi K; Klimas J; Walley A; Wood E; Fairbairn N
    PLoS One; 2020; 15(6):e0234809. PubMed ID: 32555667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methamphetamine Use: A New Wave in the Opioid Crisis?
    Fogger SA
    J Addict Nurs; 2019; 30(3):219-223. PubMed ID: 31478970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacotherapeutic strategies for methamphetamine use disorder: mind the subgroups.
    Soares E; Pereira FC
    Expert Opin Pharmacother; 2019 Dec; 20(18):2273-2293. PubMed ID: 31671001
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacotherapy of methamphetamine addiction: an update.
    Elkashef A; Vocci F; Hanson G; White J; Wickes W; Tiihonen J
    Subst Abus; 2008; 29(3):31-49. PubMed ID: 19042205
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.